Dicerna Pharmaceuticals Annual Revenue, Competitors, Number of Employees and Funding
Estimated Revenue & Financials
- Dicerna Pharmaceuticals's estimated annual revenue is currently $6.2M per year.
- Dicerna Pharmaceuticals received $100.0M in venture funding in October 2018.
- Dicerna Pharmaceuticals's estimated revenue per employee is $28,611
- Dicerna Pharmaceuticals's total funding is $373M.
- Dicerna Pharmaceuticals has 216 Employees.
- Dicerna Pharmaceuticals grew their employee count by 82% last year.
- Dicerna Pharmaceuticals currently has 26 job openings.
|James Weissman||Chief Business Officer||Email Available|
|Douglas Fambrough||President & Chief Executive Officer||Email Available|
|Megan Garrapy||Associate Director Human Resources||Email Available|
|Bob Brown||Cso And Svp Res & Dev||Email Available|
|Doug Fambrough||CEO/President||Email Available|
|Shanthi Ganesh||Associate Director, Pre-clinical Oncology||Email Available|
|Jack Green||Chief Financial Officer||Email Available|
|Byron Olsen||Vice President, Chief Patent Counsel||Email Available|
|Janelle Stover||Manufacturing Manager||Email Available|
|Daniel Lowry||Process Validation Manager||Email Available|
What Is Dicerna Pharmaceuticals?
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body's natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic rare disease. We expect to launch two additional GalXCTM programs in 2016, including one in cardiovascular disease targeting PCSK9 and another in an undisclosed genetic rare disease. We also have the capacity to launch up to three additional programs annually, with the intent to advance five programs into the clinic by the end of 2019. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$8.4M||42||50%||N/A|
Dicerna Pharmaceuticals News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Dicerna™ Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of ...
Chardan Capital reaffirmed their buy rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research note issued to investors on ...
It dropped, as 14 investors sold Dicerna Pharmaceuticals, Inc. shares while 20 reduced holdings. 24 funds opened positions while 30 raised ...
Dicerna Pharmaceuticals Funding
|2008-07-16||$8.4M||A||Oxford Bioscience Partners, Skyline Ventures||Article|
|2017-03-31||$70.0M||Undisclosed||Bain Capital Life Sciences||Article|
Dicerna Pharmaceuticals Executive Hires
|2010-05-07||Douglas M. Fambrough||CEO||Article|
|2012-01-05||James B. Weissman||Chief Business Officer||Article|
|2014-04-03||Pankaj Bhargava||Chief Medical Officer||Article|
|2014-12-18||Theodore T. Ashburn||SVP Product Strategy /Operations||Article|
|2015-12-16||John Green||Interim CFO||Article|
|2016-04-19||John B. Green||CFO||Article|
|2017-06-09||Ralf Rosskamp||Chief Medical Officer||Article|
|2019-02-22||Regina Paglia||SVP Human Resources||Article|
|2019-02-25||Douglas Fambrough||President and Chief Executive Officer||Article|